Therefore, all previously mentioned oxindole-based compounds should be fully investigated through the in vivo xenograft studies and accurate detection of pharmacokinetic and pharmacodynamic properties to facilitate the entrance of those scaffolds into clinical trials as promising FLT3 inhibitors versus FLT3 AML cells. The gene discussed is FLT3; the disease is acute myeloid leukemia.